ANTI-CD18 ANTIBODIES FOR USE AGAINST STROKE

Abstract: A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and/or reducing infarct size is described which involves administering an effective amount of an anti-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.

Description: ANTI-CD 18 ANTIBODIES FOR USE AGAINST STROKE This invention was made with United States government support under grant NS 1008 and NS28708 awarded bv the National Institutes of Health. The United States government has certain πgnts in me invention BACKGROUND OF THE INVENTION Field of the Invention This invention relates generally to the use or antι-CD18 antibodies tor treating strode In Darticular. it relates to the use of antι-CD18 antibodies tor improving clinical outcome by increasing cerebral blood flow and or reducing infarct size in focal ischemic stroke caused by obstruction ot a ma cereoral artery Description of Related Art Stroke is a general term for acute brain damage resulting from disease of blooα vessels Tnis presents a seπous problem to society, with about 500.000 people dying from or becoming permaneniK disaoleα by stroke in the United States each year Stroke can be classified into two mam categories hemorrhagic stroke (resulting from leakage ot blood outside of the normal blood vessels) and ischemic stroke (cerebral ischemia due to lack of biooα supply) this application is Dπmaπlv concerned with the latter The three mam mechanisms of ischemic stroke are thrombosis, embolism and svstemic hvpoperfusion (with resultant ischemia and hypoxiai in each of these types of stroke, the area of the brain that dies as a result of the lack of blood supply thereto is called an infarct Obstruction of a cerebral artery resulting from a thrombus which has built up on the wall of a brain artery is generally called cerebral thrombosis In cerebral embolism, the ocαusive material blocking the cerebral artery arises downstream in the circulation (e g an embolus is earned to the cerebral artery from the heart) Because it is difficult to discern whether a stroke is caused by thrombosis or embolism, the term thromboemboltsm is used to cover both these types of stroke Svstemic φoperfusion may aπse as a consequence ot decreased blood levels, reduced hematocπt. low blood pressure or inabilirv of the heart to pump blood adequateK When symptoms of stroke last less than 24 hours and the patient recovers compieteK the patient is said to have unαergone a transient ischemic attack (TIA) The symptoms of TIA are a temporan impairment of speech vision, sensation or movement. Because a TIA is often thought to be a prelude to rull-scale stroke, patients having suffered a TIA are candidates for prophylactic stroke therapy with anticoa ulation agents (e g , coumaππ and hepaπn) or antiplatelet agents (such as aspirin and ticlopidine) for example Thrornboiytic agents, such as tissue plasminogen activator (t-PA). have been used in the treatment of thromboemboiic stroke These molecules function σy lysing the thrombus causing the ischemia Such drugs are believed to be most useful if administered as soon as possible after acute stroke (preferably within 3 hours) in order to at least partially restore cerebral blood flow in the ischemic region and to sustain neuronai viability In that sucn drugs exacerbate bleeding, their use in hemorrhagic stroke is conrra-indicated A family of adhesion glycoprotems present on leukocytes is cailed the integrtn family This integπn family includes LFA- 1 (CD I la/CD 18), Mac- 1 (CD I lb/CD 18) and pi 50,95 (CD 1 lc/CD 18) A further member of this family CD 1 Id/CD 18 has recently been reported. Danilenko et αl J Immunol 155 35-44 ( 1995) Each of these heterodimers has a unique α-chaιn (CDl la, b, c ord) and the invariant β-chaιn (CD18 CD 18 integrins located on leukocytes bind to intercellular adhesion molecule- 1 (ICAM- 1 ) which is expressed on vascular enαoiheiium and other cells thereby mediating leukocyte adhesion and transendothelial migration - ι - It has been noted that CD 1 la and CD 18 are upregulated in leukocytes from patients who have undergone ischemic stroke or a TIA. Kim et a .. J. Neuroiog Sci. 128( 1 ):45-50 ( 1995). Schroeter et al.. J. Neurotmmunology 55(2): 195-203 (1994) found that increased expression of ICAM-1 on vessels and leukocytes occurred following cerebral ischemia induced by permanent occlusion of the middle cerebral aπery (MCA) in the rat. The role of cell adhesion molecules in brain injury following transient MCA occlusion in the rat has been studied (Matsuo et al.. Brain Research 656:344-352 ( 1994)). Matsuo et al. inserted a nylon thread from the lumen of the external carotid aπery ( ECA) to that of the right internal carotid artery (1CA) in order to occlude the origin of the right MCA. The occlusion was transient: after I hour, the nylon thread was removed to allow complete reperfusion of the ischemic area via the right common carotid aπery (CCA). Anti-CDl la (WTI). anti-CD18 (WT3) and anti-ICAM- 1 ( 1A29) antibodies were administered before ischemia and immediately after reperfusion. These researchers found that treatment with individual antibodies against cell adhesion molecules reduced edema formation, infarct size and neutrophil accumulation following reperfusion. Others have investigated the effects of antibodies against cell adhesion molecules in such transient stroke models. Zhang et al.. Brain Research 698:79-85 (1995) studied the effects of anti-CDl lb and anti-CD18 monoclonal antibodies in ischemia reperfusion injury, wherein the antibodies were administered upon and after transient MCA occlusion (the origin of the MCA was transiently blocked with a surgical nylon filament). Mori et al. Stroke 23(5): 712-718 (1992) studied the effects of the anti-CD18 IB4 antibody in their baboon model of reversible MCA occlusion. In this model, aπerial obstruction was achieved by inflating an extrinsic MCA balloon to l OOμl. Reperfusion occurred following balloon deflation. See, also. Chopp et al.. Stroke 25(4):869- 876 (1994) and Chen et al.. Annals of Neurology 35(4): 458-463 (1994) concerning an anti-CDl 1 b antibody in a transient cerebral ischemia model. Chopp et at., and Chen et al.. advanced a surgical nylon suture into the ICA to block the origin of the MCA. Reperfusion was accomplished by withdrawing the suture until the tip cleared the ICA lumen. Takeshima et al.. Stroke. 23(2):247-252 (1992) found that the antι-CD18 antibody 60.3 did not afford protection from severe focai ischemia and reperfusion in a transient focal cerebral ischemia model in cats. Takeshima et al. used a microvascular clip to occlude the MCA and occiuded CCAs by tightening previously placed ligatures. Lindsberg et al. J. Neurosurg. 82:269-277 (1995) subjected rabbits to severe spinal cord ischemia (by inflating the balloon of a catheter tip which had been introduced in the abdominal aorta) followed by 30 minutes of reperfusion at which time either: ( 1 ) vehicle, (2) anti-CD 18 antibody, or (3) anti-CD 18 antibody and platelet- activating factor (PAF) antagonist were administered to the animals. Recovery of motor function was improved by the anti-CDl 8 antibody, but no further improvement was induced by the PAF antagonist. It has been observed that while an anti-CD 18 antibody reduced neurologic deficits in the reversible spinal cord model (involving a snare ligature occluding device), it was unable to do so in an irreversible microsphere model. Clark e, al.. Stroke 22(7): 877-883 (1991). Clark et al. conclude that leukocytes potentiate their effect in centrai nervous system injury via reperfusion injury. With respect to anti-CDl l b antibodies. Chopp et al.. Stroke 25( 1 ):267 ( 1994) repoπ that benefit from administration of such antibodies was observed under conditions of transient, but not permanent. MCA occlusion in rats. See. also, Jiang et al.. Neuroscience Research Communications 15(2) 85-93 ( 1994) Clark et ai J \eurosura 75(4) 623-627 ( 19 1 ) also observe that while antι-ICAM- 1 produced a significant reduction in neurological deficits in the reversible spinal cord ischemia model, such therapeutic benefit was not seen in the irreversible brain ischemia model Similar findings in relation to antι-ICAM-1 antibodies have also been repoπed Zhang et al Stroke 26(8) 1438- 1442 ( 1995) Bowes et al Neurology 45 815-819 ( 1995) evaluaied the ability ot monoclonal antibodies directed against ICAM- 1 and CDl 8 to enhance the efficacy ot thrombolysis in a rabbit cerebral embolism stroke model In this model numerous small blood clots (formed by fragmenting a clot with a tissue homogenizer) were injected into the rabbit's carotid circulation in orαer to achieve embohzation Neurologic function in each animal was evaluated 18 hours following embohzation on a three point scale ( 1 ) normal activity. (2) abnormal activity. or (3) death The amount of clot necessary to produce permanent neurologic damage in 50% of the rabbits (ED 50 ) was determined for each treatment group Bowes et al found that when administration ot anti-CDl 8 or antι-ICAM-1 was delayed until 15 or 30 minutes after embohzation. a statistically significant improvement in neurologic function was not observed See also Bowes et al Experimental Neurology 1 19(2) 215-219 (1993) in relation to earlier work by this group regarding anti-ICAM- 1 and t-PA in their rabbit cerebral embolism stroke model Bednar e. al Stroke 23( 1 ) 152 (1992) describe a rabbit model of thromboembolic stroke wherein the arterial occlusion (an autologous blood clot delivered to the anterior cerebrai circulation) is not removed during the experiment Rabbits received either anti-CD 18 antibody IB4 (Img/kg), or vehicle. 30 minutes following the thromboembolic event Following embohzation, the animals were studied for a total of 4 hours, including an initial 45 minutes of systemic hypotension No statistically significant difference in cerebrai blood flow (CBF) or infarct size between IB4 and vehicle treated animals was seen However. IB4 did attenuate mtracranial hypertension in this model It is an object of the present invention to provide a method for improving clinical outcome in acute ischemic stroke by increasing cerebrai blood flow and/or reducing infarct size Furthermore, it is an object of the invention to provide an alternative to thrombolytic therapy for treating thromboembolic stroke particularly «nere thrombolvtic therapv has been unsuccessful or is contra-indicated, as is the case where tne patient to be treated is taking aspirin, or where the time delav from the onset of stroke to diagnosis is such that thrombolytic therapy is not recommended Other objects will be apparent from the description which follows SUMMARY OF THE INVENTION This application is based on the unexpected finding that anti-CD 18 antibodies can lead to a significant increase in cerebral blood flow and/or reduction in brain infarct size in focal ischemic stroke, in the absence of removal of the arterial obstruction Accordingly, the invention provides a method for treating stroke in a mammal (e g focal ischemic stroke caused by obstruction of a main cerebral artery) which comprises the step of administering an amount of CD18 antagonist and/or CDl lb antagonist to the mammal which is effective for increasing cerebral blood flow and or reducing cerebral infarct size in the mammal In the method, the arterial obstruction (generally a single thrombus or embolus) is not removed by mechanical means (e g by surgically removing the obstruction) or chemical means (e g by using a thrombolytic agent to dissolve the arterial obstruction) Furthermore, the recipient of the CD18 or CDl lb antagonist is not subjected to extraneous ss stemic hypotension (_ ■ g . via controlled exsanguiπation) during the method as was the case in Bednar e/ α/.. Stroke 23( 1 )- 152 ( 1992) Preferably the antagonist is an antι-CD18 antibody, sucn as a humanized F(ab')-, fragment Conveniently, the antagonist is administered to the mammal in the form of a pharmaceutically acceptaole formulation, such as those elaborated in more detail herein. The preferred mode of administration of the antagonist is by bolus intravenous dosage. In ceπain embodiments of the invention, the antagonist may be administered at least once a time between about 1 minutes to about 20 hours and preferably between about 30 minutes to about 12 hours from the onset of focal ischemic stroke. Single or multiple dosages may be given. Alternatively, or in addition, the antagonist may be administered via continuous infusion. In another aspect, the invention relates to a method for treating ischemic stroke caused by systemic hypopertusion or hypoxia in a mammal (e.g. resulting from cardiac arrest or drowning) which comprises the step of adπιu.ιs.eπng a therapeutical ly effective amount of CD 1 1 b antagonist and or CD 18 antagonist to the mammal. The preferred antagonist for use in this method is an anti-CD 18 antibody. Preferably, the method results in an increase in cerebral blood flow and a decrease in infarct size resulting from the svstemic hypopertusion In yet another embodiment, the invention provides a method for increasing cerebral blood flow and/or reducing infarct size in focal ischemic stroke caused by obstruction of a main cerebral aπery which comprises the step of administering a therapeutically effective amount of CD 18 and/or CDl lb antagonist to the mammal at least once at a time more than 15 mins {e.g. more than 30 mins) and preferably less than 24 hours from the onset of focal ischemic stroke in the mammal. In the method, the mammal being treated is not subjected to extraneous systemic hypotension as described in Bednar et al.. Stroke 23(1): 152 (1992). Preferably the antagonist is an anti-CD 18 antibody which is administered at least once at a time between about 30 minutes to about 12 hours from the onset of focal ischemic stroke According to the method of the previous paragraph, a therapeutically effective amount of a thrombolytic agent (such as t-PA) may be co-administered to the mammal either before, after, or simultaneously with, the CDl lb or CDl 8 antagonist. Preferably, the antagonist is administered to the mammal prior to administration of the thrombolytic agent. According to this method, the thrombolytic agent may be administered to the mammal more than about 3 hours after the onset of ischemic stroke (e.g., at least once within about 3-8 hours and preferably within about 3-5 hours from the onset of stroke). The thrombolytic agent may be administered by one or more bolus doses or by continuous infusion, for example. The invention also provides aπicles of manufacture and kits for use in the above methods. Brief Description of the Drawings Fig. I is a bar graph depicting brain infarct size (% hemisphere infarcted) in embohzed rabbits following treatment with MHM23 (antι-CD18) and t-PA (n=5); MHM23 alone (n=5); t-PA alone (n= 10) or saline solution control (n=10) as described in Example 1 (mean +/- standard error of the mean). Fig. 2 depicts regional cerebral blood flow (CBF; cc/I Ogm/min) over time in e bolized rabbits following treatment with MHM23 (antι-CD18) and t-PA (n=5): MHM23 alone (n=5): t-PA alone (n=10) or saline solution control (n=10) as described in Example 1 MHM23 or saline solution control was administered 1 hour following embohzation t-PA or saline solution control was administered bv continuous infusion over hours 3-5 following embohzation (mean * - standard error of the mean) Fig 3 illustrates intracranial pressure (ICP, mm Hg) in embolized rabbits following treatment with MHM23 (antι-CDI 8ϊ and t-PA (n=5). MHM23 alone (π=5), t-PA alone <n=10) or saline solution control (n=IO) 5 as described in Example 1 MHM23 or salme solution control was administered 1 hour following embohzation t-PA or saline solution control was administered by continuous infusion over hours 3-5 following embohzation (mean ->-/- standard error of the meanj. Figs 4A-B depict an alignment ot the relevant portions of the consensus ammo acid sequences of the human IgG , CHI domain (SEQ ID NO 1 ). the human igG 2 CHI domain (SEQ ID NO 2) the human IgG j CHI 10 αomam (SEQ ID NO 3), the human IgG 4 CH I domain ( SEQ ID NO 4) the human K C L domain (SEQ ID NO 5). and the human λ C L domain (SEQ ID NO 6), in alignment with the Fabv I b variant derived from an anti- CDl 8 antibody (SEQ ID NO 7) In Figs 4 A-B. ammo acid residues and/or positions ot interest and of most importance for use as salvage receptor binding epitopes within the sequence of Fabvlb (i e . SEQ ID NOS- 8 and 9) are designated bv underlining and asterisks respectively ' 5 Detailed Description ot the Preferred Embodiments I. Definitions "Focal ischemic stroke" is defined herein as damage to the brain caused by interruption of the blood supply to a region thereof The focal ischemic stroke of interest herein is generally caused obstruction of any one or more of the "main cerebral arteries" (e g middle cerebral aπery. anterior cerebral aπery. posterior 0 cerebral aπery, internal carotid aπery. veπebral aπery or basilar aπery), as opposed to secondary aπeries or a teπoies The "aπeπal obstruction" is generally a single embolus or thrombus Hence, tocal ischemic stroke as defined herein is distinguished from the cerebrai embolism stroke model of Bowes et al Neurology 45 815- 819 (1995) in which a plurality of clot panicles occlude secondary aπeries or aπeπoles The expression "in the absence of removal of the arterial obstruction" when used througnout this 5 application means that the aπeπal obstruction is essentially not removed bv mechanical means (for example, by physicalh removing the obstruction as described in the transient stroke models described above) or bv chemical means such as removal of a thrombus or embolus using a thrombolytic agent, see, e g , Bowes et al Neurology 45.815-819 (1995)) prior to a therapeutic benefit achieved by administration of the CDI8 or CDl lb antagonist (r e , the increase in cerebral blood flow and or the reduction in infarct size) However, this term would 0 encompass situations wherein the arterial obstruction is slightly reduced in size as a consequence of endogenous thrombolytic molecules dissolving part of the thrombus/embolus, provided that at least some (e g , about 50% and preferably about 80%) of the arterial obstruction remains intact following any such size reduction By "increasing cerebrai blood flow or reducing infarct size" is meant the act of improving clinical outcome by inducing a statistically or physiologically significant increase in cerebral blood flow and/or a statistically or physiologically significant reduction in infarct size in a treated mammal relative to an untreated mammal as determined using techniques which are well known in the an. such as vascular imaging, for example Preferably cerebral blood flow as determined 2-4 hours after administration of the antagonist is increased by at least 30% and preferably at least 50% relative to an untreated mammal Desirably, infarct size measured 48 hours alter administration of the antagonist will be 20% less and preferably 50% less than tnat of an untreated mammal The term "CD 18 antagonist" when used herein refers to a molecule which binds to CDl 8 (preferably human CD 18) and inhibits or substantially reduces a biological activity of CDl 8 Normally the antagonist will block (partially or completely) the ability of a cell (e g a neutrophil) expressing the CD 18 subunit at its cell surface to Dind to endotheiium Non-limiting examples of CD18 antagonists include antibodies proteins, peptides glycohpids. polvsacchaπdes. oligosacchaπdes. nucleic acids, bioorganic molecules peptidomimetics. pharmacological agents and their metabolites transcriptionai and translation control sequences and the like In the preferred embodiment of the invention, the CDl 8 antagonist is an antibodv Examples of antι-CDI 8 antibodies include MHM23 (Hildreth et αl Ear J Immunol 13 202-208 (1983)), Ml 8/2 (IgG 2a , Sanches-Madπd et al J Exp Med 158 586 (1983)), H52 (American Type Culture Collection (ATCC) Deposit HB 10160). Masl91c and IOT18 (Vermot Desroches et al Scand J Immunol 33 277-286 (19 1)). and NA-8 (WO 94/12214) The preferred antibody is one which binds to the CD18 epitope to which either MHM23 or H52 binds Preferably the antibody has a high affinity tor the CDl 8 polypeptide in preferred emoodiments the antibodv has an affmitv for the CD 18 antigen of about 4nM or less Preferably the affinitΛ is aoout 3nM or less, and most preferably I nM or less In certain embodiments, the antibodv may bind to a region in the extracellular domain of CD 18 which associates with CDl lb and the antibody may also dissociate α and β chains e g the antibodv may dissociate the CDl lb and CD! 8 complex as is the case for the MHM23 antibody) The term "CDl lb antagonist" when used herein refers to a molecule which binds to CDl lb and inhibits or substantialK reduces a biological activity of CDl l b Normally, the antagonist will block (paπiallv or completely ) the ability of a cell (e g a neutrophil) expressing the CDl lb subunit at its cell surface to bind to endotheiium Non-limiting examples of CDl I b antagonists include antibodies, proteins peptides. glycoDroteins, glycopeptides glyco pids polysacchaπdes, oligosacchandes nucleic acids bioorganic molecules, peptidomimetics. pharmacological agents and their metabolites transcriptionai and translation control sequences, and the like The preferred CDl lb antagonist is an antibody especially an anti-CDl lb antibodv which binds human CDl lb Exemplary CDl lb antibodies include MY904 (US Patent 4.840,793) l B6c (see Zhang et al Brain Research 698 79-85 ( 1995)), CBRN 1/5 and CBRM 1/I9 (WO94/08620) The term "antibody" is used in the broadest sense and specifically covers monoclonal antibodies. antibody compositions with polyepitopic specificity, bispecific antibodies, diabodies. and single-chain molecules, as well as antibody fragments (e g , Fab, F(ab')->, and Fv), so long as they antagonize the biological activity of CDl lb or CDlδ The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies. / e , the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts Monoclonal antibodies are highly specific, being directed against a single antigenic site Fuπhermore, in contrast to conventional (polyclonal) antibody preparations which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen In addition to their specificity, the monoclonal antibodies are advantageous in that they are synthesized bv the hvbπdoma culture uπcontammated b other immunoglobulins The modifier monoclonal indicates the character or the antibodv as being obtained from a substantially homogeneous population or antibodies, and is not to be construed as requiring production or the antibody bv anv particular method For example, the monoclonal antibodies to be used in accordance with the present invention mav be made b\ the hvbπdoma method first described bv Kohler et al Nature.256 495 ( 1975), or mav be made recombinant DNA methods ■ see, e g L S Patent No 4 816,567) The "monoclonal antibodies' mav also be isolated from pnage antibody libraries using the techniques described in Clackson et ai Nature 352 624-628 ( 1 91 ) and Marks et al J Mol Biol . 222 581-597 (1991 ). for example The monoclonal antibodies herein specifically include "chimeric antibodies (immunogiooulins) in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or Belonging to a particular antibodv class or subclass while the remainder of the chaιn(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibodv class or subclass, as well as fragments of such antibodies, so long as thev exhibit the desired biological activity (U S Patent No 4,816.567. Momson et at Proc Natl Acad Set USA 81 6851-6855 ( 1984)) 'Humanized' forms of non-human {e g muπne) antibodies are chimeric immunoglobulins, immunoglobu n chains or fragments thereof (such as Fv. Fab, Fab F(ab') 2 or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobuhn For the most pan. humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary-determining region (CDR) of the recipient are replaced by residues from a CDR of a non- human species I αonor antibody) such as mouse, rat or rabbit having the desired specificity, affinity, and capacity In some instances Fv framework region (FR) residues of the human immunoglobuhn are replaced by corresponding non-human residues Furthermore, numanized antibodies mav comprise residues which are found neither in the recipient antibody nor in the impoπed CDR or framework sequences These modifications are made to ruπher refine and optimize antibody performance In general the humanized antibodv will comprise -ubstannalh all of at least one and typically two variable domains, in which all or substantiall y all of the CDR regions correspond to those of a non-human immunoglobuhn and all or substantially all of the FR regions are those ot a human immunoglobuhn sequence The humanized antibody optimally also will comprise at least a Dortion ot an immunoglobulin constant region (Fc), typically that of a human immunoglobuhn For further details, see Jones et al . Nature, 321 522-525 (1986), Reichmann et al Nature, 332 323-329 (1988), and Presta. C rr Op Struct Biol . 2.593-596 (1992) The humanized antibodv includes a Pπmatized™ antibody wherein the antigen-binding region of the antibody is derived from an antibody produced by immunizing macaque monkeys with the antigen of interest "Single-chain Fv" or "sFv" antibody fragments comprise the V H and V^ domains of antibody wherein these domains are present in a single polypeptide chain Generally, the Fv polypeptide further comprises a polypeptide linker between the V H and V L domains which enables the sFv to form the desired structure for antigen binding For a review of sFv see Pluckthun in The Pharmacology of Monoclonal Antibodies, vol 1 13, Rosenbur and Moore eds . Spnnger-Verlag, New York, pp 269-315 ( 1994) The term diabodies ' refers to small antibodv tragments with two antigen-oinding sites wnich fragments compπse a heaw-cham variable domain (V ) connected to a light-chain variable domain (V^ ι in the same polypeptide chain ( V H - V^) Bv using a linker that is too shoπ to allow pairing between tne two domains on the same chain, the domains are forced to pair with the complementary domains of another chain and create two antigen-binding sites Diabodies are described more fully in tor example EP 404 097 WO 93/1 1 161 ana Hollinger et al Proc Natl Acad Sci USA, 90 6444-6448 ( 1993) As used herein, the term 'salvage receptor binding epitope' refers to an epitope ot the Fc region of an IgG molecule (e g , IgG j , IgG 2 , IgG 3 , and IgG 4 ) that is responsible for increasing the in vivo serum half-life of the IgG molecule "Treatment" refers to both therapeutic treatment and prophylactic or preventative measures Those in need of treatment include those already with the disorder as well as those in which the disorder is to be prevented This application is mostly concerned with treating those individuals who have been diagnosed as having suffered acute ischemic stroke "Mammal" for purposes of treatment refers to any animal classified as a mammal, including humans domestic and farm animals and zoo sports or pet animals, such as dogs horses cats cows etc Preferably the mammal is human A "thrombolytic agent" is a molecule which breaks up or dissolves a thrombus Exemplary thrombolytic agents include streptokinase. acylated plasminogen-strepto ase activator complex ( APSAC) urokinase single- chain urokinase-plasminogen activator (scu-PA), thrombmlike enzvmes from snake venoms such as ancrod (Bell. W "Defribmogenating enzymes' In Colman et al (eds) Hemostasis and Thrombosis Lippincott Philadelphia (1987) p 886). tissue plasminogen activator (t-PA) and biologically active variants ot each of the above The preferred thrombolytic agent is t-PA In the context of the present invention, the terms "tissue plasminogen activator ' and "t-PA" are used interchangeably and denote extrinsic (tissue type) plasminogen activator having at least two functional domains consisting of a protease domain that is capable of converting plasminogen to plasmin and an N-terminal region believed to be responsible for fibrin binding These terms theretore include polvpeptides containing these functional domains as part ot the overall ammo acid sequence irrespective of their source and method of preparation (e g these terms cover vampire bat t-PAs as disclosed in EP 352, 1 19) The terms "human tissue plasminogen activator" and "human t-PA" are used interchangeably and denote wild-type human tissue plasminogen aαivator and functional derivatives thereof Examples of t-PA functional derivatives include those molecules with extended half-life and improved fibrin specificity as disclosed in WO 93/24635, N-terminally truncated t-PA vaπants (see EP 382.174) and C84S t-PA descnbed in Suzuki et al J Cardiovasc Pharmacol 22.834-840 (1993). for example II. Modes for Carrying out the Invention The invention provides a method for treating focal ischemic stroke such as thromoboembolic stroke In particular, cerebrai blood flow can be increased and/or infarct size can be reduced in focal ischemic stroke by administering an effective amount of a CDl lb and or CD 18 antagonist to the mammal having suffered the stroke In this method, the arteπal obstruction is not removed prior to observation of the therapeutic benefit as defined herein, and as such the method does not require prior administration of a thrombol y tic agent to the mammal in order to remove an embolus/thrombus and thereby increase cerebral blood flow ana or reduce infarct size. It is contemplated that the CD18 or CDl la antagonist ot the present invention will be administered to a patient as soon as possible once the condition of acute ischemic stroke has been diagnosed or is suggested by focal deficit on neurologic examination. Neurologic examination and. optionally, neuroimaatng techniques such as computed tomography (CT) and magnetic resonance imaging (MRJ) (including diffusion weignted imaging (DWT) and perfusion imaging (PI)); vascular imaging (e g , duplex scanning and transcranial Doppler ultrasound and laser Doppler); angiography (e g , computerized digital subtraction angiography (DSA) and MR angiography) as well as other invasive or non-invasive techniques are available for the diagnosis of acute ischemic stroke Preferably, the CDl 8 or CDl la antagonist will be administered at least once or continuously at anytime from immediately following to about 24 hours after the onset of stroke In certain embodiments, the CD 18 or CDl la antagonist is first administered to the patient at a time between about 15 minutes lor 30 minutes or 45 minutes) to about 5 hours (or 12 hours or 24 hours) from the onset of stroke For example, the antagonist may be first admmistered by bolus dosage as soon as stroke is diagnosed, followed by a subsequent bolus dosage of the antagonist e g 5-24 hours after the initial bolus dosage) The preferred antagonist for use in the above method is humanized H52 antibody (huH52). especially the huH52 F(ab') 2 antibody fragment The sequence of the heavy chain of the huH52 Fab is: EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYTMHWMRQAPG GLEWVAGINPKNGGTSHNQRF MDRFTISVDK.STSTAYMQMNSLRAEDTAVYYCARWRGLNYGFDVRYFDVWGQGTLVTVSSASTK GPSVFPLAPSSKSTSGGTAALGCLV DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV PSSSLGTQTYICNVNHKPSNTKVDK VEP SCDKTHT (SEQ ID NO- 10) The sequence of the light chain of the huH52 Fab is: DIQMTQSPSSLSASVGDRVTITCRASQDΓN YLNWYQQ PGKAPKLLIYYTSTLHSGVPSRFSGSGSG TDYTLTISSLQPEDFATYYCQQGNTLPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLL NNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYE HKVY ACEVTHQGL SSPVTKSFNRGEC (SEQ ID NO 1 1 ) In other embodiments, the full length IgGτ huH52 antibody may be the molecule of choice. The heavy chain of the full length IgG-, huH52 antibody has the sequence- EVQLVESGGGLVQPGGSLRLSCATSGYTFTEYTMHWMRQAPGKGLEWVAGINPKNGGTSHNQRF MDRFTISVDKSTSTAYMQMNSLRAEDTAVYYCARWRGLNYGFDVRYFDVWGQGTLVTVSSASTK GPSVFPLAPCSRSTSESTAALGCLV DYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVT SSNFGTQTYTCNVDH PSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVT CVVVDVSHEDPEVQFNWYVDGMEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEY CKV SNKGLPAPIE T1SKT GQPREPQVYTLPPSREEMTKNQVSLTCLV GFYPSDIAVEWΕSNGQPENN YKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQ SLSLSPGK(SEQIDNO: 12). The light chain of the full length IgG-> huH52 antibody has the sequence- DIQMTQSPSSLSASVGDRVTITCRASQDINNYLNWYQQKPG APKLLIYYTSTLHSGVPSRFSGSGSG TDYTLTISSLQPEDFATYYCQQGNTLPPTFGQGT VEI RTVAAPSVFIFPPSDEQLKSGTASVVCLL NNFYPREAKVQWKVDNALQSGNSQESVTEQDS DSTYSLSSTLTLSKADYEKHKVYACEVTHQGL SSPVTKSFNRGEC (SEQ ID NO: 13). A description follows as to the production of the preferred antagonists {i.e. antibodies), long half-life antagonists, pharmaceutical formulations, modes for administration, as well as kits and articles of manufacture for use in the claimed methods. The description in relation to long half-life antagonists, pharmaceutical formulations and modes for administration is also relevant to the use of thrombolytic agents in certain embodiments of the invention. A. Antibody Preparation According to the preferred embodiment of the invention, the CD 18 or CDl lb antagonist is an antibody. Various antibodies which bind to CD18 and CDl lb are available in the art. Furthermore, a description follows as to the production of anti-CD 18 or anti-CDl lb antibodies for use in the treatment of stroke as defined herein. (i) Polyclonal antibodies. Polyclonal antibodies are generally raised in animals by multiple subcutaneous (sc ) or intrapeπtoneai (ip) injections of the relevant antigen and an adjuvant, it may be useful to conjugate the relevant antigen to a protein that is immunogenic in the species to be immunized, e.g., keyhole limpet hemocyanin. serum albumin. bovine thyrogiobulin. or soybean trypsin inhibitor using a bifunctional or derivatizing agent, for example, maleimidobenzoyl sulfosuccinimide ester (conjugation through cysteine residues). N-hydroxysuccinimide (through lysine residues), glutaraldehvde. succinic anhydride. SOG , or R'N=C=NR. where R and R 1 are different alkyl groups. Animals are immunized against the antigen, immunogenic conjugates, or derivatives by combining 1 mg or I μg of the peptide or conjugate (for rabbits or mice, respectively) with 3 volumes of Freund's complete adjuvant and injecting the solution intradermaily at multiple sites. One month later the animals are boosted with 1/5 to 1/ 10 the original amount of peptide or conjugate in Freund's complete adjuvant by subcutaneous injection at multiple sues. Seven to 14 days later the animals are bled and the serum is assayed for antibody titer. Animals are boosted until the titer plateaus. Preferably, the animal is boosted with the conjugate of the same antigen, but conjugated to a different protein and/or through a different cross-linking reagent. Conjugates also can be made in recombinant cell culture as protein fusions. Also, aggregating agents such as alum are suitably used to enhance the immune response. (it) Monoclonal antibodies. Monoclonal antibodies are obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Thus, the modifier "monoclonal" indicates the character of the antibody as not being a mixture of discrete antibodies. For example, the monoclonal antibodies may be made using the hybridoma method first described by Kohler et al.. Nature. 256:495 (1975), or may be made by recombinant DNA methods ( U.S. Patent No. 4.816,567). In the hybπdoma method, a mouse or other appropriate host animal such as a namster is immunized as hereinabove described to elicit lvmphocvtes that produce or are capable ot producing antibodies that will specifically bind to the protein used for immunization Alternatively lymphocytes mav be immunized in vitro Lvmphocvtes then are fused with myeloma cells using a suitable fusing agent such as polv ethvlene glycol. to form a tivbπdoma cell (Goding, Monoclonal Antibodies Principles and Practice pp 59- 103 (Academic Press 1986)) The hybπdoma cells thus prepared are seeded and grown in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfuseo parental mveioma cells For example, if the parental myeloma cells lack the enzvme hypoxanthine guanine phosphoπbosv l transferase (HGPRT or HPRT), the culture medium for the hybπdomas typically will include hvpoxanthme aminopteπn, and thymidine (HAT medium), which substances prevent the growth of HGPRT-deficient cells Preferred myeloma cells are those that fuse efficiently, support stable high-level production of antibody by the selected antibodv-producing cells, and are sensitive to a medium such as HAT medium Among these. preferred myeloma cell lines are muπne myeloma lines, such as those derived from MOPC-21 and MPC-1 1 mouse tumors available from the Salk Institute Cell Distribution Center San Diego California USA and SP-2 cells available from the American Type Culture Collection, Rockville, Maryland USA Human mveioma and mouse-human heteromyeloma ceil lines also have been described for the production of human monoclonal antibodies (Kozbor../ Immunol , 133 3001 ( 1984), Brodeur e. α/ Monoclonal Antibodv Production Techniques and Applications, pp 51-63 (Marcel Dekker. Inc New York. 1987)) Culture medium in which hybπdoma cells are growing is assayed for production of monoclonal antibodies directed against the antigen Preferably the binding specificity of monoclonal antibodies produced bv hybπdoma cells is determined by immunoprecipitation or by an in vitro binding assav such as radioimmunoassay (RJA) or enzyme-linked immunoabsorbent assay (ELISA) The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson et al Anal Btochem 107 220 ( 1980) After hybπdoma cells are identified that produce antibodies of the desired specificirv aπ.nity. and/or activity, the clones mav be subcloned by limiting dilution procedures and grown bv standard methods (Goding, Monoclonal Antibodies Principles and Practice, pp 59-103 (Academic Press. 1986)) Suitable culture media for this purpose include, for example, D-MEM or RPM1- 1640 medium In addition, the hvbπdoma cells may be grown in vrvo as ascites tumors in an animal The monoclonal antibodies secreted by the subclones are suitably separated from the culture medium, ascites fluid, or serum by conventional immunoglobuhn purification procedures such as, for example, protein A-Sepharose hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography DNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures (e g , by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of muπne antibodies) The hybπdoma cells serve as a preferred source ot such DNA Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as £ coh cells, simian COS cells Chinese hamster ovary (CHO) cells, or myeioma cells that do not otherwise produce immunoglobuhn protein to obtain the synthesis of monoclonal antibodies in the recombinant host cells Review articles on recombinant expression in bacteria of DNA encoding the antibody include Skerra et al Curr Opinion in Immunol . 5:256-262 (1993) and PlUckthun. Immunol Revs . 130 151- 188 ( 1992) In a further embodiment, antibodies or antibody fragments can oe isolated from antibody phage libraries generated using the techniques described in McCafferry et at . Nature. 348:552-554 ( 1990) ClacKson et at Nature, 352.624-628 ( 1991 ) and Marks ei al . J Mol Biol.. 222:581 -597 ( 1991 ) describe the isolation of murine and human antibodies, respectively, using phage libraries. Subsequent publications describe the production oi high affinity (nM range) human antibodies by chain shuffling (Marks etal.. Bio/Tec/motogy, 10:779-783 ( 1992)). as well as combinatorial infection and in vivo recombination as a strategy for constructing very large phage libraries Waterhouse et al.. Nuc Acids. Res.. 21 :2265-2266 ( 1993)). Thus, these techniques are viable alternatives to traditional monoclonal antibody hybridoma techniques for isolation of monoclonal antibodies The DNA also may be modified, for example, by substituting the coding sequence for human heavy- and light-chain constant domains in place of the homologous murine sequences (U S. Patent No. 4.816.567. Morrison, et al.. Proc. Natl Acad. Set. USA. 81 :6851 ( 1984)), or by covaiently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Typically such non-immunoglobulin polypeptides are substituted for the constant domains of an antibody, or they are substituted for the variable domains of one antigen-combining site of an antibody to create achimenc bivalent antibody comprising one antigen-combining site having specificit y for an antigen and another antigen-combining site having specificity for a different antigen. Chimeric or hybrid antibodies also may be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxms may be constructed usmg a disulfide-exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include tminothiolate and methyl-4-mercapιobutyπmιdate. (iii) Humanized and human antibodies Methods for humanizing non-human antibodies are well known in the an. Generally, a humanized antibody has one or more ammo acid residues introduced into it from a source which is non-human. These non- human ammo acid residues are often referred to as "import" residues, which are typically taken from an import ' variable domain. Humanization can be essentially performed following the method of Winter and co-workers (Jones et al.. Nature. 321:522-525 (1986); Riechmann et al.. Nature, 332.323-327 ( 1988); Verhoeyen et al . Science. 239:1534- 1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816.567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies. The choice of human variable domains, both light and heavy, to be used in making the humanized antibodies is very important to reduce antigenicirv. According to the so-called "best-fit" method, the sequence of the variable domain of a rodent antibody is screened against the entire library of known human variable- domain sequences. The human sequence which is closest to that of the rodent is then accepted as the human framework (FR) for the humanized antibodv (Sims et al . J. Immunol . 151 :2296 ( 1 93); Chothia et al . J Mol Biol . 196 901 ( 1987)) Another method uses a particular framework derived from the consensus sequence of all human antibodies of a particular subgroup or light or heavy cnains The same trameworκ mav be used for several different humanized antibodies (Caπer ei al Proc Natl Acad Sci LSA 89 4285 ( 1992). Presta et al J Immnol 1 1 2623 (1993)) It is further important that antibodies be humanized with retention of high affinit y tor the antigen and other favorable biological properties To achieve this goal, according to a preferred method humanized antibodies are prepared bv a process of analysis of the parental sequences and various conceptual humanized products using three-dimensional models ot the parental and humanized sequences Three-dimensional immunoglobuhn models are commonly available and are familiar to those skilled in the an Computer programs are available which illustrate and display probable three-dimensional contormational structures of selected candidate immunoglobuhn sequences Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobuhn sequence i e , the analysis of residues that influence the ability of the candidate immunoglobuhn to bind its antigen In this wav, FR residues can be selected and combined from the recipient and import sequences so that the desired antibodv characteristic, such as increased affinity tor the target antιgen(s) is achieveα In general, the CDR residues are directly ana most substantially involved in influencing antigen binding Alternatively it is now possible to produce transgenic animals (e g , mice) that are capable upon immunization, ot producing a full repertoire of human antibodies in the absence of endogenous lmmunoglobulin production For example it has been described that the homozygous deletion ot the antibodv heaw-chain joining region (J H ) gene in chtmeπc and germ-line mutant mice results in complete inhibition of endogenous antibody production Transfer of the human germ-line immunoglobuhn gene aπay in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge See. e g , Jakobovits et al Proc Natl Acad Sci USA. 90 2551 ( 1993) Jakobovits et al Nature. 362 255-258 (1993), Bruggermann et al Year in Immuno , 7 33 (1993) Human antibodies can also be derived from phage- display libraries (Hoogenboom et at J Mol Biol . 227 381 ( 1991 ), Marks et al J Mol Biol . 222 581 -597 ( 1991 )) I ιv) Bispecific antibodies Bispecific antibodies (BsAbs) are antibodies that have binding specificities for at least two different epuopes Exemplary BsAbs may bind to two different epitopes of the CD 18 antigen or may bind both CD 18 and CDl lb Such antibodies can be derived from full length antibodies or antibodv fragments (e g F(ab') 2 bispecific antibodies) Methods for making bispecific antibodies are known in the art Traditional production of full length bispecific antibodies is based on the coexpression of two immunoglobuhn heavy chain-light chain pairs, where the two chains have different specificities (Millstetn et al Nature, 305 537-539 (1983)) Because of the random assortment of lmmunoglobulin heavy and light chains, these hybπdomas (quadromas) produce a potential mixture of 10 different antibodv molecules, of which only one has the correct bispecific structure Purification of the correct molecule, which is usually done by affinity chromatography steps, is rather cumbersome, and the product y ields are low Similar procedures are disclosed in WO 93/08829, published 13 May 1993 and in Traunecker et al EMBO J . 10 3655-3659 (1991 ) According to a different and more preferred approacn. antibodv variable domains with the desired binding specificities (antibody-antigen combining sites) are fused to immunoglobuhn constant domain sequences The fusion preferably is with an immunoglobuhn heavy chain constant domain, comprising at least pan of the hinge, CH2. and CH3 regions. It is preferred to have the first heavy-chain constant region (CHI ) containing the site necessary for light chain binding, present m at least one of the fusions DNAs encoding the lmmunoglobulin heavy chain fusions and. if desired, the immunoglobuhn light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism This provides for great flexibility in adjusting the mutual proportions of the three polypeptide fragments in embodiments when unequal ratios of the three polypeptide chains used in the construction provide the optimum vields It is. however, possible to insert the coding sequences for two or all three polypeptide chains in one expression vector when the expression of at least two polypeptide chains in equal ratios results in high yields or when the ratios are of no particular significance In a preferred embodiment of this approach, the bispecific antibodies are composed of a hybrid lmmunoglobulin heavy chain with a first binding specificity in one arm. and a hvbπd immunoglobuhn heavy chain-light chain pair (providing a second binding specificity) in the other arm It was found that this asvmmemc structure facilitates the separation or the desired bispecific compound from unwanted immunoglobuhn chain combinations, as the presence of an immunoglobuhn light chain in only one half of the bispecific molecule provides for a facile way of separation This approach is disclosed in WO 94/04690 published March 3. 1994 For further details of generating bispecific antibodies see. tor example, Suresh et at Methods in Enzvmotogy, 121:210 (1986) Using such techniques, a bispecific molecule which combines a thrombolytic agent such as t-PA and n antι-CD18 or anti-CDl lb antibody can be prepared for use in the treatment of stroke as defined herein Bispecific antibodies include cross-linked or "heteroconjugate" antibodies For example, one of the antibodies in the heteroconjugate can be coupled to avidin. the other to biotm Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (US Patent No 4 676,980). and for treatment of HIV infection (WO 91/00360. WO 92/200373. and EP 03089) Heteroconjugate antibodies may be made using any convenient cross-linking methods Suitable cross-linking agents are well known in the art. and are disclosed in US Patent No 4.676 980. along with a number of cross-linking techniques Techniques for generating bispecific antibodies from antibody fragments have also been described in the literature The following techniques can also be used for the production of bivalent antibody fragments which are not necessaπly bispecific For example. Fab' fragments recovered from E coli can be chemically coupled in vitro to form bivalent antibodies. See. Shalaby et al , J Exp Med . 175 217-225 ( 1992) Various techniques for making and isolating bivalent antibody fragments directly from recombinant cell culture have also been described For example, bivalent heterodimers have been produced using leucine zippers ostelny et al . J Immunol . 148(5).1547-1553 ( 1992) The leucine zipper peptides from the Fos and Jun protems were linked to the Fab' portions of two different antibodies by gene fusion The antibody homodimers were reduced at the h ge region to form monomers and then re-oxidized to form the antibody heterodimers. The "dιabody ' technology descnbed by Hollmger e. al Proc Natl Acad Sci USA. 90 6444-6448 ( 1993) has provided an alternative mechanism for making bispecific/bivalent antibody fragments The fragments comprise a heavy-chain variable domain (V H ) connected to a light-chain variable domain (V L ) by a linker which is too short to allow pairing between the two domains on the same chain Accordingly, the V H and V L domains of one fragment are forced to pair with the complementary V L and V ( j domains of another fragment thereov forming two antigen-binding sites Another strategy tor making bispecific/bivalent antibodv fragments b\ the use of single-chain Fv (sFv) dimers has also been reported See Gruber et al J Immunol 152 5368 ( 1994) B. Long half-life antagonists In certain emoodiments of the invention, it is desirable to use CD18 or CDl l b antagonists engineered to have an ennanced half-life in the serum of a mammal treated therewith For example this mav be achieved by (i) incorporating a salvage receptor binding epitope of the Fc region of an IgG into the antagonist so as to increase its circuiatorv half-life but without disrupting us biological activity or ( n) covaleπtlv binding a nonproteinaceous polymer to the antagonist These exemplary techniques will be described briefly below (i) Antagonist-salvage receptor binding epitope fusions Incorporation of a salvage receptor binding epitope into the antagonist can take place bv anv means such as by mutation of the appropriate region in the antagonist of interest to mimic the Fc region or by incorporating the epitope into a peptide tag that is then fused to the antagonist at either end or in the middle or by DNA or peptide synthesis A systematic method for preparing such an antagonist variant having an increased in vivo half-life comprises several steps The first involves identifying the sequence and conformation of a salvage receptor binding epitope of an Fc region of an IgG molecule Once this epitope is identified the sequence of the antagonist of interest is modified to include the sequence and conformation of the identified binding epitope After the sequence is mutated, the antagonist variant is tested to see if it has a longer in vivo half-life than that of the ongmal antagonist If the antagonist variant does not have a longer in vivo half-life upon testing, its sequence is further altered to include the sequence and conformation of the identified binding epitope The altered antagonist is tested for longer in vtvo half-life, and this process is continued until a molecule is obtained that exhibits a longer in vtvo half-life The salvage receptor binding epitope being thus incorporated into the antagonist of interest is any suitable such epitope as defined above, and its nature will depend, e . on the tvpe of antagonist being modified The transrer is made such that the antagonist of interest is still able to antagonize the biological activity of CDl lb or CD 18 Where the antagonist of interest is an antibody, it contains an Ig domain or Ig-like domain and the salvage receptor binding epitope is placed so that it is located within this Ig domain or Ig-like domain More preferabl y , the epitope constitutes a region wherein any one or more ammo acid residues from one or two loops of the Fc domain are transferred to an analogous position of the Ig domain or Ig-like domain of the antibody Even more preferably, three or more residues from one or two loops of the Fc domain are transferred Still more preferred, the epitope is taken from the CH2 domain of the Fc region (e g , of an IgG) and transferred to the CHI. CH3, or ' H region, or more than one such region, of an Ig or to a Ig-like domain Alternatively, the epitope is taken from the CH2 domain of the Fc region and transferred to the C L region or V L region or both, of an Ig or to an Ig-like domain of the antagonist of interest For example, for purposes of discussing variants wherein the poiypeptide of interest is an antibody, reference is made to Figs 4A-B. which illustrates the relevant consensus primary structures of various Igs, ; e . human IgG ] CH I domain, human IgG 2 CHI domain, human IgG 3 CHI domain, human IgG CH I domain, human κC L domain, and human ΛC L domain as well as the specific sequence tor Fabv 1 b a preferred anti-CD 18 Fab variant herein Fuπher Figs 4A-B indicates the residues ot Fabv l b that are ot interest and of most importance In a preferred embodiment the resiαues or importance are those with an asterisk in Figs 4A-B . e in one loop of Fabv l b MIS with a T residue one am o aciα C-terminal to MIS and in another loop of Fabv l b HQN with a D residue two amino acids C-terminal to HQN and a K residue one amino acid C-terminai to the D residue In one most preferred embodiment, the salvage receptor binding epitope compπses the sequence (5 to 3')- PKNSSMISNTP (SEQ ID NO 8). and optionally further comprises a sequence selected from the group consisting of HQSLGTQ (SEQ ID NO 14), HQNLSDGK (SEQ ID NO 9) HQNISDGK (SEQ ID NO 15) or VISSHLGQ (SEQ ID NO 16), particularly where the antagonist of interest is a Fab or F(ab') 2 (u) Antagonist-polymer conjugates The nonproteinaceous polymer ot choice for this purpose is ordinaπlv is a nydrophilic synthetic polymer, i e , a polymer not otherwise found in nature However, polymers which exist in nature ana are produced bv recombinant or in vitro methods are useful as are polymers which are isolated from native sources Hvdrophilic polvvinvl polymers fall within the scope of this invention e ς polvvinvlalcohol and polyvinylpyrroiidone Particularly useful are polvalkvlene ethers such as polyethylene glycol (PEG), polyelkvlenes such as poiyoxyethylene polyoxypropylene. and block copolvmers of polvoxyethvlene and poiyoxypropylene (Pluronics). polymethacrviates carbomers branched or unbrancned polysacchaπoes wnich compnse the sacchande monomers D-mannose, D- and L-galactose. fucose, fructose, D-xylose L-arabmose, D- glucuronic acid, siaiic acid, D-galacturonic acid, D-mannuronic acid (e g polymannuronic acid or alginic acid), D-glucosamine, D-galactosamine D-glucose and neuraminic acid including homopolvsacchaπdes and heteropolysacchaπdes such as lactose, amylopectm. starch, hydroxyethyl starch, amylose. dextrane sulfate, dextran. dextπns, glycogen, or the polysacchaπde subunit of acid mucopolysacchaπdes, e g hyaluronic acid, polymers of sugar alcohols such as polysorbitol and poiymannitol hepaπn or heparon The polymer prior to cross-linking need not be. but preferably is water soluble but the finai conjugate must be water soluble In addition the polymer should not be highly immunogenic in the coniugate form, nor should it possess viscosity that is incompatible with intravenous infusion or injection if it is intended to be administered bv such routes Preferably the polymer contains only a single group which is reactive This helps to avoid cross-itnking of protein molecules However, it is within the scope herein to optimize reaction conditions to reduce cross- linking, or to punfy the reaction products through gel filtration or chromatographic sieves to recover substantially homogenous derivatives The molecular weight of the polymer may desirably range from about 100 to 500,000. and preferably is from about 1.000 to 20,000 The molecular weight chosen will depend upon the nature of the polymer and the degree of substitution In general the greater the hydrophilicitv of the poiymer and the greater the degree of substitution, the lower the molecular weight that can be employed Optimal molecular weights will be determined by routine experimentation The polymer general lv is covalentlv linked to the antagonist though a multifunctional crosslinking agent which reacts with the polymer and one or more amino acid or sugar residues of the antagonist to be linked However, it is within the scope of the invention to directly crosslink the polymer bv reacting a derivatized polymer with the hybrid, or vice versa. Covalent binding to ammo groups is accomplished bv known chemistries based upon cvanuπc chlonde. carbonyl diimtdazole. aldehyde reactive groups ( PEG alkoxide plus diethyl acetal of bromoacetaldehyde: PEG plus DMSO and acetic anhydride, or PEG chloride plus the phenoxide of 4-hydroxvbenzaldehyde. succinimidyl active esters, activated dithiocarbonate PEG. 2.4.5-tπchloroohenylcloroformate or P-nitrophenylcloroformate activated PEG). Carboxyl groups are derivatized by coupling PEG-amine using carbodiimide Polymers are conjugated to oligosacchaπde groups by oxidation using chemicals, e.g metapeπodate. or enzymes, e g glucose or galactose oxidase. (either of which produces the aldehyde derivative of the carbohydrate), followed by reaction with hydrazide or amino derivatized polymers, in the same fashion as is described by Heitzmann et al.. Proc. Natl Acad Sci USA 71 :3537-41 ( 1974) or Bayer et at Methods in Enzvmotogy 62.310 ( 1979). for the labeling of oligosacchaπdes with biotin or avidin. Fuπher. other chemical or enzymatic methods which have been used heretofore to link oligosaccnarides are paπiculariy advantageous because, in general, there are fewer substitutions than ammo acid sites for deπvatization. and the oligosaccharide products thus will be more homogenous. The oligosaccharide substituents also are optionally modified by- enzyme digestion to remove sugars, e g by neuramimdase digestion, prior to polymer derivatization. The polymer will bear a group which is directly reactive with an amino acid side chain, or the N- or C- terminus of the antagonist linked, or which is reactive with the multifunctional cross-linking agent. In general, polymers bearing such reactive groups are known for the preparation of immobilized proteins. In order to use such chemistries here, one should employ a water soluble polymer otherwise derivatized in the same fashion as insoluble polymers heretofore employed for protein immobilization. Cyanogen bromide activation is a particularly useful procedure to employ in crosslinking polysaccnarides. "Water soluble" m reference to the staπing polymer means that the polymer or its reactive intermediate used for conjugation is sufficiently water soluble to participate in a derivatization reaction "Water soluble" in reference to the polymer conjugate means that the conjugate is soluble in physiological fluids such as blood. The degree of substitution with such a polvmer will vary depending upon the number of reactive sites on the antagonist, whether all or a fragment of the antagonist is used, whether the antagonist is a fusion with a heterolo ous protein (e.g. anti-CD 18 antibody fused to a salvage receptor binding epitope), the molecular weight, hydrophilicity and other characteristics of the polymer, and the particular antagonist derivatization sites chosen. In general, the conjugate contains about from 1 to 10 polymer molecules, while any heterologous sequence may be substituted with an essentially unlimited number of polymer molecules so long as the desired activity is not significantly adversely affected. The optimal degree of cross-linking is easily determined by an experimental matnx in which the time, temperature and other reaction conditions are varied to change the degree of substitution, after which the ability of the conjugates to function in the desired fashion is determined. The polymer, e.g PEG. is cross-linked by a wide variety of methods known per se for the covalent modification of proteins w ith nonprotemaceous polymers such as PEG. The long half-life conjugates of this invention are separated from the unreacted starting materials by gel filtration. Heterologous species of the conjugates are purified from one another in the same fashion. The polymer also may be water-insoluble, as a hydrophilic gel. C. Pharmaceutical Formulations Therapeutic formulations of the CD l l b or CD 18 antagonist are prepared tor storage by mixing the antagonist having the desired degree of purity with optional physiologically acceptable carriers. or stabilizers {Remington's Pharmaceutical Sciences 16th edition. Osol, A. Ed. ( 1980)). in the form o lyophiiize d formulations or aqueous solutions. Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate and other organic acids; antioxidants including ascorbic acid: low molecular weight (less than about 10 residues) poiypeptides; proteins, such as serum albumin, gelatin or immunoglobulins: ammo acids such as glycine. glutam e. asparagme. histidme. arginine or lysine: monosaccharides, disaccharides and other carbohydrates including glucose. mannose. trehalose or dextnns: chelating agents such as EDTA: sugar alcohols such as mannitol or sorbitol: salt- forming counteπons such as sodium: and or nonionic surfactants such as Tween. Pluronics or PEG. The active ingredients may also be entrapped in microcapsuies prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylceliulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsuies. respectively, in colloidal drug delivery systems (for example, liposomes. albumin microspheres. microemulsions, nano-particies and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences 16th edition. Osol. A. Ed. ( 1980). The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes, prior to or following iyophihzation and reconstitution. Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the CD 18 or CD 1 1 b antagonist, which matrices are in the form of shaped articles, e.g. films, or microcapsuies. Examples of sustained-reiease matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacryiate). or poly(vιnylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ ethyl-L-glutamate. non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the Lupron Depot™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(-)-3- hydroxyburyπc acid. While polymers such as ethvleπe-vmyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods. When encapsulated antibodies remain in the body for a long time, they may denature or aggregate as a result of exposure to moisture at 37° C. resulting m a loss of biological activity and possible changes in immunogeniciry. Rational strategies can be devised for stabilization depending on the mechanism involved. For example, if the aggregation mechanism is discovered to be lntermolecular S-S bond formation through thio-disulfide interchange, stabilization may be achieved by modifying suifhydryl residues, lyophilizing from acidic solutions, controlling moisture content, using appropriate additives, and developing specific polymer matrix compositions. Sustained-release CD18 or CDl l b antagonist compositions also include liposomally entrapped antagonists. Liposomes containing the CDl 8 or CDl lb antagonist are prepared by methods known in the art, such as described in Epstein et al , Proc Natl. Acad Set. USA. 82.3688 (1985): Hwang et al . Proc Natl Acad Sci USA. 77 4030 (1980); and U.S. Pat. Nos 4.485,045 and 4.544.545. Ordinarily, the liposomes are the small (about 200-800 Angstroms) unilameiartype in which the pid content is greater than about 30 mol % cholesterol, - I B - the selected proportion being ad j usted for the optimal CD 18 or CDl l b antagonist therap y Liposomes with enhanced circulation time are disclosed in U S Patent No 5 013.556 D. Modes for Administration The CD 18 or CD l l b antagonists of the invention are administered to a mammal preterar.lv a human. in accord with known methods such as intravenous administration as a bolus or bv continuous inrusion over a period of time by intramuscular, intraperitoneai. intracerobrospinal. subcutaneous, lntra-amcular. mtrasvnovial. lntrathecal. oral, topical, or inhalation routes Intravenous administration of the antagonist is oreterreα The appropriate dosage of CD18 or CDl l b antagonist will depend on the nature of the stroke to be treated, the seventy and course of the stroke, whether the antagonist is aαmmistered for preventive or therapeutic purposes previous therapy, the patient's clinical history and response to the CD 18 or CD ] l b antagonist and the discretion of the attending physician The CD! 8 or CDl l b antagonist is suitably administered to the patient at one time or over a series of treatments and may be administered to the patient at any time from diagnosis onwards For example, the antagonist may be administered at a time between about 15.30 or 45 minutes to about 5 hours 12 hours or 24 hours from the onset of stroke In preferred embodiments, the initial dose is followed bv at least one subsequent dose ( g from 5 to 24 hours after the initial dose) In certain situations CDl l b antagonist and CD 18 antagonist are co-ad mistered to the mammal Where the antagonist is an antibody, from about I OOμg/kg to about 20mg kg. and preferably from about 500μg kg to about 5 g kg, and most preferably from about lmg/kg to about 3mg/kg of the antι-CD18 or anti- CDl lb antibody is an initial candidate dosage for administration to the patient whether, for example, by one or more separate administrations, or by continuous infusion However, other dosage regimens may be useful The progress of this therapy is easily monitored bv conventional techniques and assays elaborated herein E. Kits and Articles of Manufacture In another embodiment of the invention, there are provided articles of manufacture and kits containing materials useful for improving clinical outcome in stroke by increasing cerebral blood flow and/or reducing infarct size The article of manufacture comprises a container with a label Suitable containers include, for example bottles vials, and test tubes The containers mav be formed from a variety of materials such as glass or Diastic The container holds a composition which is effective for treating stroke as defined herein and may have a sterile access port (for example the container may be an intravenous solution bag or a \ ιai having a stopper pierceable by a hypodermic injection needle) The active agent in the composition is a CD 1 1 b or CD 18 antagonist The label on the container indicates that the composition is used for treating stroke as described above, and may also indicate directions for in vivo use, such as those described above The kit of the invention comprises the container described above and a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline. Ringer's solution and dextrose solution It may further include other mateπals desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use The following examples are offered by way of illustration and not by way of limitation The disclosures of all citations in the specification are expressly incorporated herein by reference EXAMPLE This studv investigated the effect of anti-CDl 8 antibody (MHM23) and t-PA in a rabbit model of thromboembolic stroke In this model a single blood clot is introduced into the middle cerebral and posterior communicating aπeries (which are 'mam cerebral aπeries 1 The arterial obstruction w e the clot) remains in place throughout the experiment (unless it is enzymatically removed by t-PΛ) The following rabbit model is thought to correlate weil with the physiological progression of thromooembolic stroke in numans Materials and Methods The rabbit model of thromboembolic stroke used in the current studv has been previously described in detail (Bednar et al . Neurol Res 16 129- 132 (1994). Gross et al Stroke 24 558-562 ( 1993). Kohut et at Stroke, 23.93-97 (1992), Wilson et al Neurosurgerv 31 929-934 ( 1992)) See. also. Gross ei at Neurosurgery, 36(6).1 172- I I 77 ( 1995) Briefly, New Zealand white rabbits (Charles River, CA) (both males and females, 3 0-3 5kg) were anesthetized with the solution of ketamine (50mg/kg, Aveco Co . Fort Dodge, IA). acepromazine (20 mg. Aveco Co.), and xylazine (5 mg/kg, Mobay Corp., Shawnee, KS). a solution that was subsequently used to maintain sufficient anesthesia for painless surgery (as determined by responses to various physiological and autonomic stimuli, including mean arterial pressure and response to a paw being pinched) After an incision was made in the nght femoral mangle to expose the femoral vein and aπery. the femoral aπery was cannulated with a PE-90 catheter (BD Co . Parsippany. NJ). to which was attached a platinum-indium electroαe This catheter-eiectroαe permitted the continuous measuring of mean arterial pressure and blood sampling tor measurement of arterial blood gases (ABG) (pH, PC0 2 , PO- ). hematocπt, and glucose and for determination of hydrogen washout to assess the rCBF bv the hydrogen clearance technique (Young, Stroke 1 1 552-564 ( 1980)) After the femoral vein was cannulated with PE-90 tubing for drug infusions, a midline scalp incision was made to expose the calvaπum. Bilateral craniectomies were performed and the following were placed. 30-gauge platinum-indium electrodes to monitor the regional cerebral blood flow (rCBF), a fiberoptic, epidural intracranial pressure (ICP) monitor (Princeton Medical Corp . Hudson. NH); and a temperature sensor (Yellow Springs Instruments, Yellow Springs, OH) to measure brain temperature. All cranial instrumentation was carefully fixed in place with fast- setting epoxy Through a midline neck incision, the animal was tracheostomized and mechanically ventilated Both depth and rate of ventilation were modified as needed to maintain ABGs within physiological range Throughout the experiment, the brain and core temperatures, mean arterial pressure, and ICP were continuously measured. Additionally, the following parameters were measured before embohzation (baseline). at the time of embohzation, and hourly after embohzation: the rCBF. hematocπt. glucose, and ABG The mean arteπal pressures were kept between 50 and 60 mm Hg throughout the experiment Fluids (Ringer's lactate or packed cells) were given intravenously as needed (approximately 2-4 ml kg/h) to maintain euvolemia Core and brain temperatures were maintained within 1 ° C of baseline by using heating blankets and heating lamps The autologous clot was prepared by mixing the whole blood (1 ml) with 50 mg of tin granules The clot was introduced into the PE-90 tubing pretreated with thrombin and was allowed to mature at room temperature. After tracheostomy, the region of the bifurcation of the common carotid artery was identified, followed by 30 to 60 minutes of equilibration, during which baseline values were obtained All surgery was completed within 2 hours Once all the baseline values were obtained, the proximal internal carotid artery and the distal common carotid artery were transiently isolated from the circulation An arteπotomy was then performed, and the autologous ciot embolus delivered to the anterior circulation of the brain via a catheter advanced into 'he proximal internal carotid artery Once emooiized both the proximal internal carotiα aπerv ana distal common carotid artery were again isolated from the circulation and an aπeπonhaphv w as pertormed bv using 10-0 interrupted nylon sutures A Philip s dental machine was used to obtain a submentai-veπex raαiograpn that verified placement of the tin-tagged clot Emboiized clots were noted within the middle cerebral and posterior communicating aπeries t-PA or a saline solution (0 9% saline i was administered intravenously by continuous infusion from hours 3-5 after the embohzation at a total dose of 6 3 mg kg MHM23 (2 g/kg) was administered by bolus dosage 1 hour after embohzation In each instance, the experiment continued for 7 hours after embohzation Submental-vertex radiographs were obtaineα after embohzation an at the end of the experiment Immediately after the embohzation. the rCBF was measured again, the experiment was continued if the rCBF w as ≤ 15 ml/100 g,' mm in any of the three electrodes in the emboiized hemisphere (Jones et al J Neurosurg 54 773-782 ( 1981 )) At the end of the experiment, the animals were killed with an overdose of sodium pentobarbital ( 150 mg/kg) a procedure recognized as acceptable ana painless, according to the euthanasia guidelines of the American v eterinary Medical Association Bilateral thoracotomies w ere performed in accordance with procedures outlined by the University of Vermont Institutional Animal Care and Utilization Committee The brain was harvested rapidly and examined grossly for the presence and position of residual clot The brain was cut into 2-mm slices in a bread-loaf fashion and incubated in tπphenyltetrazolium chloride d e to define the size of the brain infarct (Bose et al . Stroke 19 28-37 ( 1988)) This method has been shown to be an acceptable means of determining the size of a brain infarct in our rabbit model and correlates well with hematoxy n and eostn staining (Bednar et al N nrol Res 16 129- 132 ( 1994)) Each brain slice was carefull y traced onto clear acetate sheets for later planimemc determination of the infarct size, for which an IBM image analvzer was used The infarct size was determined according to the modification described by Lin et al Stroke 24 1 17- 121 (1993) In this method the region of the infarct is determined by subtracting the voiume of the noninfarcted pan of the emboiized hemisphere rrom the entire volume ot the nonembolized hemispnere This modification takes into account that the volume ot a brain infarct mav be overestimated because of associated swelling The analysis ot variance for repeated measures was used to analyze the hematocπt glucose, ABG, rCBF. and ICP in the control and treated groups If significance was noted, the values of these variables immediatel y before the t-PA and or MHM23 administration were then compared by the Student's . test When necessary the analysis of covaπance was used to compare the control and treated groups After a significant treatment-by-ttme interaction, individual contrasts were used to compare the treatment means at each time point, that is, if a significant treatment-by-time interaction was noted, the treatment effects were examined at each time point The infarct size and specific gravities of the brain were compared (treated versus control) by the Student's t test All the results v^ ere two-sided and were evaluated by using α = 0 05 Results The results of the above experiment are depicted in Figs 1 -3 As shown in Figs 1 and 2, administration of antι-CD18 antibody alone, lead to a significant increase in cerebral blood flow as well as a significant reduction in infarct size relative to control Fig 3 shows that anti-CDl 8 antibody alone. t-PA alone, or a combination of these two agents tend to reduce intracranial pressure (ICP) at 6-7 hours Furthermore, the experiments show that antι-CD18 antibodv is compatable with t-PA and improves me outcome of t-PA when given at 3-5 hours after installation of the clot into the cerebral circulation. The increase in cerebral blood flow and the reduction in infarct size observed in the above experiments are thought to be predictive of an improvement in clinical outcome as measured b> a standard stroke scale. Accordingly, this application provides a method for improving clinical outcome in patients having suffered stroke as defined herein. The model described in this example differs from that previously described in Bednar et al . Stroke 23(1 ): 152 (1992) in that the animals in the study were not subjected to extraneous sy stemic hypotension (by reducing the mean arterial pressure in the animal to 30 mmHg by controlled exsanguination) Also, the anti- CD 18 antibody was given more than 30 minutes after the thromboembolic event and the dose was different. SEQUENCE LISTING '1) GENERAL INFORMATION: (1) APPLICANT: Genentech, Inc. University of Vermont and State Agricultural College (ll) TITLE OF INVENTION: ANTI-CD18 ANTIBODIES IN STROKE (ill) NUMBER OF SEQUENCES: 16 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Genentech, Inc. (B) STREET: 460 Point San Bruno Blvd (C) CITY: South San Francisco (D) STATE: California (E) COUNTRY: USA (F) ZIP: 94080 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk '3) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOΞ/MS-DOS (D) SOFTWARE: WinPatm (Genentech) (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: I ill) ATTORNEY/AGENT INFORMATION: (A) NAME: Lee, Wendy M. (B) REGISTRATION NUMBER: 40,378 (C) REFERENCE/DOCKET NUMBER: P0987PCT tiκ) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: 415/225-1994 ,B) TELEFAX. 415/952-9881 (C) TELEX: 910/371-7168 .2) INFORMATION FOR SEQ ID NO:l: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 98 ammo acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1 : Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser 1 5 10 15 Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys 20 25 30 Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 35 40 45 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser 50 55 60 Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 65 70 75 Leu Gly Thr Gin Thr Tyr lie Cys Asn Val Asn His Lys Pro Ser 80 85 90 Asn Thr Lys Val Asp Lys Arg Val 95 98 (2) INFORMATION FOR SEQ ID NO:2 : (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 98 amino acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2 : Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser 1 5 10 15 Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys 20 25 30 Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 35 40 45 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser 50 55 60 Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn 65 70 75 Phe Gly Thr Gin Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser 80 85 90 Asn Thr Lys Val Asp Lys Thr Val 95 98 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 98 amino acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (XI) SEQUENCE DESCRIPTION: SEQ ID NO: 3 : Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser 1 5 10 15 Arg Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys 20 25 30 Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 35 40 45 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser 50 55 60 Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 65 70 75 Leu Gly Thr Gin Thr Tyr Thr Cys Asn Val Asn His Lys Pro Ser 80 85 90 Asn Thr Lys Val Asp Lys Arg Val 95 98 Z ) INFORMATION FOR SEQ ID NO:4: ll) SEQUENCE CHARACTERISTICS (A) LENGTH: 98 am o acids (B) TYPE: Ammo Acid (D) TOPOLOGY. Linear xi) SEQUENCE DESCRIPTION. SEQ ID NO:4 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser 1 5 10 15 Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys 20 25 30 Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala 35 40 45 Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin Ser Ser 50 55 60 Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 65 70 75 Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser 80 85 90 Asn Thr Lys Val Asp Lys Arg Val 95 98 ' 2 , INFORMATION FOR SEQ ID NO: 5 : (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 107 ammo acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: Arg Thr Val Ala Ala Pro Ser Val Phe He Phe Pro Pro Ser Asp 1 5 10 15 Glu Gin Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn 20 25 30 Asn Phe Tyr Pro Arg Glu Ala Lys Val Gin Trp Lys Val Asp Asn 35 40 45 Ala Leu Gin Ser Gly Asn Ser Gin Glu Ser Val Thr Glu Gin Asp 50 55 60 Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser 65 70 75 Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr 80 85 90 His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly 95 100 105 Glu Cys 107 (2) INFORMATION FOR SEQ ID NO:6 : (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 105 amino acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Gin Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser 1 5 10 15 Glu Glu Leu Gin Ala Asn Lys Ala Thr Leu Val Cys Leu He Ser 20 25 30 Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser 35 40 45 Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gin 50 55 60 Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro 65 70 75 Glu Gin Trp Lys Ser His Arg Ser Tyr Ser Cys Gin Val Thr His 80 85 90 Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser 95 100 105 (2) INFORMATION FOR SEQ ID NO: 7 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 100 amino acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Pro 1 5 10 15 Lys Asn Ser Ser Met He Ser Asn Thr Pro Ala Leu Gly Cys Leu 20 25 30 Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 35 40 45 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gin 50 55 60 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro His 65 70 75 Gin Ser Leu Gly Thr Gin Thr Tyr He Cys Asn Val Asn His Lys 80 85 90 Pro Ser Asn Thr Lys Val Asp Lys Arg Val 95 100 12) INFORMATION FOR SEQ ID NO: 8 • (i) SEQUENCE CHARACTERISTICS. (A) LENGTH: 11 ammo acids (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8 : Pro Lys Asn Ser Ser Met He Ser Asn Thr Pro 1 5 10 11 (2) INFORMATION FOR SEQ ID NO: 9: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 amino acids IE) TYPE: Amino Acid (D) TOPOLOGY. Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9 : His Gin Asn Leu Ser Asp Gly Lys 1 5 8 (2) INFORMATION FOR SEQ ID NO:10: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 232 amino acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi ) SEQUENCE DESCRIPTION: SEQ ID NO:10: Glu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly 1 5 10 15 Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Tyr Thr Phe Thr 20 25 30 Glu Tyr Thr Met His Trp Met Arg Gin Ala Pro Gly Lys Gly Leu 35 40 45 Glu Trp Val Ala Gly He Asn Pro Lys Asn Gly Gly Thr Ser His 50 55 60 Asn Gin Arg Phe Met Asp Arg Phe Thr He Ser Val Asp Lys Ser 65 70 75 Thr Ser Thr Ala Tyr Met Gin Met Asn Ser Leu Arg Ala Glu Asp 80 85 90 Thr Ala Val Tyr Tyr Cys Ala Arg Trp Arg Gly Leu Asn Tyr Gly 95 100 105 Phe Asp Val Arg Tyr Phe Asp Val Trp Gly Gin Gly Thr Leu Val 110 115 120 Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 125 130 135 Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 140 145 150 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 155 160 165 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 170 175 180 Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 185 190 195 Pro Ser Ser Ser Leu Gly Thr Gin Thr Tyr He Cys Asn Val Asn 200 205 210 His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys 215 220 225 Ser Cys Asp Lys Thr His Thr 230 232 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 214 amino acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (xi! SEQUENCE DESCRIPTION: SEQ ID NO: 11: Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val 1 5 10 15 Gly Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Asp He Asn 20 25 30 Asn Tyr Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys 35 40 45 Leu Leu He Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr He 65 70 75 Ser Ser Leu Gin Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin 80 85 90 Gly Asn Thr Leu Pro Pro Thr Phe Gly Gin Gly Thr Lys Val Glu 95 100 105 He Lys Arg Thr Val Ala Ala Pro Ser Val Phe He Phe Pro Pro 110 115 120 Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu 125 130 135 Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gin Trp Lys Val 140 145 150 Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin Glu Ser Val Thr Glu 155 160 165 Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr 170 175 180 Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu 185 190 195 Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn 200 205 210 Arg Glv Glu Cvs ' 214 12) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 450 ammo acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear ixi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: Glu Val Gin Leu Val Glu Ser Gly Gly Gly Leu Val Gin Pro Gly 1 5 10 15 Gly Ser Leu Arg Leu Ser Cys Ala Thr Ser Gly Tyr Thr Phe Thr 20 25 30 Glu Tyr Thr Met His Trp Met Arg Gin Ala Pro Gly Lys Gly Leu 35 40 45 Glu Trp Val Ala Gly He Asn Pro Lys Asn Gly Gly Thr Ser His 50 55 60 Asn Gin Arg Phe Met Asp Arg Phe Thr He Ser Val Asp Lys Ser 65 70 75 Thr Ser Thr Ala Tyr Met Gin Met Asn Ser Leu Arg Ala Glu Asp 80 85 90 Thr Ala Val Tyr Tyr Cys Ala Arg Trp Arg Gly Leu Asn Tyr Gly 95 100 105 Phe Asp Val Arg Tyr Phe Asp Val Trp Gly Gin Gly Thr Leu Val 110 115 120 Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 125 130 135 Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly 140 145 150 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp 155 160 165 Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 170 175 180 Leu Gin Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 185 190 195 Thr Ser Ser Asn Phe Gly Thr Gin Thr Tyr Thr Cys Asn Val Asp 200 205 210 His Lys Pro Ser Asn Thr Lys Val Asp Lys Thr Val Glu Arg Lys 215 220 225 Cys Cys Val Glu Cys Pro Pro Cys Pro Ala Pro Pro Val Ala Gly 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 He Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 260 265 270 His Glu Asp Pro Glu Val Gin Phe Asn Trp Tyr Val Asp Gly Met 275 280 285 Glu Val H s Asn Ala Lys Thr Lys Pro Arg Glu Glu Gin Phe Asn 290 295 300 Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val His Gin Asp 305 310 315 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly 320 325 330 Leu Pro Ala Pro He Glu Lys Thr He Ser Lys Thr Lys Gly Gin 335 340 345 Pro Arg Glu Pro Gin Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu 350 355 360 Met Thr Lys Asn Gin Val Ser Leu Thr Cys Leu Val Lys Gly Phe 365 370 375 Tyr Pro Ser Asp He Ala Val Glu Trp Glu Ser Asn Gly Gin Pro 380 385 390 Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly 395 400 405 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp 410 415 420 Gin Gin Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 425 430 435 His Asn His Tyr Thr Gin Lys Ser Leu Ser Leu Ser Pro Gly Lys 440 445 450 12) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 214 ammo acids (B) TYPE: Amino Acid (D) TOPOLOGY: Linear (Xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: Asp He Gin Met Thr Gin Ser Pro Ser Ser Leu Ser Ala Ser Val 1 5 10 15 Gly Asp Arg Val Thr He Thr Cys Arg Ala Ser Gin Asp He Asn 20 25 30 Asn Tyr Leu Asn Trp Tyr Gin Gin Lys Pro Gly Lys Ala Pro Lys 35 40 45 Leu Leu He Tyr Tyr Thr Ser Thr Leu His Ser Gly Val Pro Ser 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr He 65 70 75 Ser Ser Leu Gin Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gin Gin 80 85 90 Gly Asn Thr Leu Pro Pro Thr Phe Gly Gin Gly Thr Lys Val Glu 95 100 105 He Lys Arg Thr Val Ala Ala Pro Ser Val Phe He Phe Pro Pro 110 115 120 Ser Asp Glu Gin Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu 125 130 135 Leu Asn Asn Phe Tyr Pro Arg Glu Ala Lys Val Gin Trp Lys Val 140 145 150 Asp Asn Ala Leu Gin Ser Gly Asn Ser Gin Glα Ser Val Thr Gld 155 160 165 Gin Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr 170 175 180 Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala C\ s Glu 185 190 195 Val Thr His Gin Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn 200 205 210 Arg Gly Glu Cys 214 (2) INFORMATION FOR SEQ ID NO: 14. (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 7 ammo acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14 His Gin Ser Leu Gly Thr Gin 1 5 7 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 ammo acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (XI) SEQUENCE DESCRIPTION: SEQ ID NO: 15: His Gin Asn He Ser Asp Gly Lys 1 5 8 (2) INFORMATION FOR SEQ ID NO:16- (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 8 ammo acids (B) TYPE: Ammo Acid (D) TOPOLOGY: Linear (xi) SEQUENCE DESCRIPTION. SEQ ID NO: 16: Val He Ser Ser His Leu Gly Gin 1 5 8

Claims: WHAT IS CLAIMED IS 1 A method for treating focal ischemic stroke caused by obstruction of a main cerebral aπery in a mammal comprising administering an amount of antι-CD18 antibody to the mammal y vhich is effective for increasing cerebral blood flow or reducing infarct size, in the absence of removal of the aπeπal obstruction 2. The method of claim 1 which increases cerebral blood flow and reduces infarct size in the mammal 3 The method of claim I wherein the antι-CD18 antibody is an antibody fragment 4 The method of claim 3 yvherein the antι-CD18 antibody fragment is a F(ab') 2 5 The method of claim 1 wherein the anti-CD 18 antibody is humanized. 6 The method of claim 1 wherein the antι-CD18 antibody is administered to the mammal by bolus dosage 7. The method of claim I wherein the antι-CDI 8 antibody is administered intravenously 8 The method of claim 1 wherein the antt-CD18 antibody is administered via continuous infusion. 9 The method of claim 1 wherein the antι-CD18 antibody is administered to the mammal at a time between about 15 minutes to about 20 hours from the onset of focal ischemic stroke. 10. The method of claim 9 wherein the anti-CD 18 antibody is administered to the mammal at a time between about 45 mins to about 5 hours from the onset of focal ischemic stroke. 1 1. The method of claim 1 wherein the anti-CDl 8 antibody is humanized H52 antibody. 12. The method of claim 1 1 wherein the H52 antibody is a F(ab') 2 13. The method of claim 3 wherein the anti-CD 18 antibody fragment is fused to a salvage receptor binding epitope 14. The method of claim 1 wherein the mammal is a human. 15. An article of manufacture, comprising: a container: a label on said container: and a composition comprising an active agent contained within said container: wherein the composition is effective for increasing cerebral blood floyv or reducing infarct size in focal ischemic stroke caused by obstruction of a main cerebral artery, the label on said container indicates that the composition can be used for treating stroke and the active agent in said composition is an antagonist anti-CD 18 antibody. 16. The article of manufacture of claim 15 further comprising instructions for administering the anti-CD 18 antibodv to a mammal to increase cerebral blood flow or reduce infarct size in focal ischemic stroke. 17. A kit. comprising. a first container, a label on said container, and a composition comprising an active agent contained within said container; wherein the composition is effective for increasing cerebral blood flow or reducing infarct size n focal ischemic stroke caused by obstruction ot a main cerebral aπery. the label on said container indicates that the composition can be used for treating stroke, ana the active agent in said composition is an antagonist antι-CD18 antibody; a second container comprising a pharmaceutically-acceptable buffer: and instructions for using the anti-CD 18 antibody to increase cerebrai blood flow or reduce infarct size in focal ischemic stroke.

Inventors: BEDNAR MARTIN M, GROSS CORDELL E, THOMAS G ROGER, BEDNAR, MARTIN, M., GROSS, CORDELL, E., THOMAS, G., ROGER
Applicants: GENENTECH INC, UNIV VERMONT, GENENTECH, INC., UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLE
Application year: 1997
Main classification: A61K39
IPC codes: A61K38, A61K39, A61P7, A61P9, C07K16, G01N33